Selected unaudited quarterly financial data for the years 2015 and 2014 are summarized below:



	2015					2014
(Dollars in Millions Except Per Share Data)	First Quarter ⁽¹⁾		Second Quarter ⁽²⁾	Third Quarter ⁽³⁾	Fourth Quarter ⁽⁴⁾	First Quarter ⁽⁵⁾	Second Quarter ⁽⁶⁾	Third Quarter ⁽⁷⁾	Fourth Quarter ⁽⁸⁾
Segment sales to customers
Consumer	$	3,390	3,483	3,314	3,320	3,557	3,744	3,589	3,606
Pharmaceutical	7,726		7,946	7,694	8,064	7,498	8,509	8,307	7,999
Medical Devices	6,258		6,358	6,094	6,427	7,060	7,242	6,571	6,649
Total sales	17,374		17,787	17,102	17,811	18,115	19,495	18,467	18,254
Gross profit	12,092		12,430	11,878	12,138	12,660	13,456	13,068	12,401
Earnings before provision for taxes on income	5,575		5,741	4,122	3,758	5,424	5,626	6,810	2,703
Net earnings	4,320		4,516	3,358	3,215	4,727	4,326	4,749	2,521
Basic net earnings per share	$	1.55	1.63	1.21	1.16	1.67	1.53	1.69	0.90
Diluted net earnings per share	$	1.53	1.61	1.20	1.15	1.64	1.51	1.66	0.89


⁽¹⁾	The first quarter of 2015 includes a net litigation gain of $253 million after-tax ($402 million before-tax) and $122 million after-tax ($139 million before-tax) for costs associated with the DePuy ASR^TM Hip program.


⁽²⁾	The second quarter of 2015 includes net litigation expense of $23 million after-tax ($134 million before-tax).


⁽³⁾	The third quarter of 2015 includes net litigation expense of $348 million after-tax ($409 million before-tax).


⁽⁴⁾	The fourth quarter of 2015 includes a restructuring charge of $415 million after-tax ($590 million before-tax), $156 million after-tax ($214 million before-tax) from impairment of in-process research and development and Synthes integration costs of $59 million after-tax ($83 million before-tax). Additionally, the fourth quarter of 2015 includes the gain on the Cordis divestiture.


⁽⁵⁾	The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.


⁽⁶⁾	The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).

⁽⁷⁾

The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASR^TM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.


⁽⁸⁾	The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.